B.Riley FBR Believes OptimizeRx Corporation (OPRX) Won’t Stop Here


B.Riley FBR analyst Andrew D’silva reiterated a Buy rating on OptimizeRx Corporation (Other OTC: OPRX) yesterday and set a price target of $20. The company’s shares opened today at $17.73, close to its 52-week high of $18.39.

D’silva said:

“Several notable events have taken place since our last update on OptimizeRx Corporation (OPRX) that, we believe, indicate positive momentum: OPRX established a partnership with Medicom Health, which continues to expand OPRX’s market reach beyond its core domestic ambulatory health system channels; also, before the open yesterday, 10/17, OPRX announced it acquired CareSpeak Communications, an interactive health messaging company focused on medication adherence and care coordination. We expect OPRX to report 3Q18 results in early November, and we believe our estimates could prove to be conservative, as we are modeling sales to be largely flat sequentially, despite the company indicating Q/Q revenue growth throughout 2018.”

According to TipRanks.com, D’silva is a 5-star analyst with an average return of 19.5% and a 46.3% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Sorrento Therapeutics, and Kindred Biosciences.

OptimizeRx Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $20.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.39 and a one-year low of $3.36. Currently, OptimizeRx Corporation has an average volume of 58.73K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records (EHR), which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. Its services include EHR workflow solutions such as financial messaging, patient education, and brand messaging; and brand support.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts